ANCHOR LEAD: CURRENTLY AVAILABLE MEDICATIONS MAY HELP AGAINST NASAL POLYPS, ELIZABETH TRACEY REPORTS
Chronic nasal inflammation with tissue overgrowth known as polyps is especially difficult for patients. Johns Hopkins research led by Jean Kim, a sinusitis expert and surgeon, has shown that a common growth factor is involved.
KIM: We looked in the nasal washes first and we identified VEGF as being the growth factor that was specifically elevated with this particular disease process. :11
Currently available VEGF inhibitors may be useful, Kim says.
KIM: There are VEGF inhibitors that are on the market that are actually currently being used, mostly in anticancer antitumor trials. We would actually like to embark upon that pathway in terms of looking at that as an alternative form of treatment and so we will be initiating studies going in that direction. :18
Vascular endothelial growth factor, or VEGF, is implicated in some types of cancer, the eye condition known as macular degeneration, and other disease processes, with drugs to inhibit the factor in clinical use. At Johns Hopkins, I’m Elizabeth Tracey.